TIO Bioventures

Treadwell Therapeutics is a clinical-stage oncology company that develops medicines to address unmet needs in patients with cancer. Founded by a cadre of pre-eminent scientific luminaries, including Dr. Tak W. Mak, the Company's robust, internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945, and a best-in-class TTK inhibitor, CFI-402257, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1. Treadwell also has a robust pre-clinical pipeline with multiple biologic and next-generation TCR-based autologous cell therapy programs.

TCRyption is a preclinical company focused on the development of novel approaches to TCR based cellular therapy for cancer and other indications. TCRyption seeks to develop a pipeline of product candidates that can treat cancer type and patient populations that are underserved by current approaches.